Literature DB >> 24323378

Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice.

Gregory J Bix1, Emma K Gowing, Andrew N Clarkson.   

Abstract

With the failure of so many pre-clinical stroke studies to translate into the clinic, there is a need to find new therapeutics to minimize the extent of cellular damage and aid in functional recovery. Domain V (DV), the c-terminal protein fragment of the vascular basement membrane component, perlecan, was recently shown to afford significant protection in multiple transient middle cerebral artery occlusion stroke models. We sought here to determine whether DV might have similar therapeutic properties in a focal photothrombosis stroke model in both young and aged mice. Young (3-month old) and aged (24-month old) mice underwent photothrombotic stroke to the motor cortex and were then treated with DV or phosphate buffered saline vehicle at different initial time points up to 7 days. Stroke volume was analyzed histologically using cresyl violet and functional recovery assessed behaviorally on both the grid-walking and cylinder tasks. In young mice, DV administration resulted in a significant decrease in infarct volume when treatment started 3 or 6 h post-stroke. In aged mice, DV administration was only protective when started 3 h post-stroke. In addition to a decrease in the area of infarction, DV treatment was effective in significantly decreasing the number of foot-faults on the grid-walking task and improving use of the stroke-affected limb in the cylinder task in both young and aged. Previously, we have shown that DV can alter the expression profile of various astroglial markers. Consistent with our previous finding, treatment groups that showed therapeutic potential in both young and aged mice also showed an elevation in glial fibrillary acidic protein (GFAP) expression in peri-infarct regions. We conclude that DV is neuroprotective and affords significant improvements in functional recovery in both young and aged mice after focal ischemia. These data also highlight a therapeutic time-window shift that is narrower in aged compared with young mice and is associated with an elevation in GFAP expression and heightened astrogliosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24323378      PMCID: PMC3937769          DOI: 10.1007/s12975-013-0266-1

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  32 in total

Review 1.  Stroke incidence and prevalence in Europe: a review of available data.

Authors:  T Truelsen; B Piechowski-Jóźwiak; R Bonita; C Mathers; J Bogousslavsky; G Boysen
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

Review 2.  Perturbed cellular response to brain injury during aging.

Authors:  Aurel Popa-Wagner; Ana-Maria Buga; Zaal Kokaia
Journal:  Ageing Res Rev       Date:  2009-11-10       Impact factor: 10.895

3.  Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.

Authors:  Gregory Bix; Remedios Castello; Michelle Burrows; Jason J Zoeller; Michelle Weech; Rex A Iozzo; Christopher Cardi; Mathew L Thakur; Christopher A Barker; Kevin Camphausen; Renato V Iozzo
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

Review 4.  Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke.

Authors:  Tania M Hansen; Andrew J Moss; Nicholas P J Brindle
Journal:  Curr Neurovasc Res       Date:  2008-11       Impact factor: 1.990

5.  Changes in experimental stroke outcome across the life span.

Authors:  Fudong Liu; Rongwen Yuan; Sharon E Benashski; Louise D McCullough
Journal:  J Cereb Blood Flow Metab       Date:  2009-02-18       Impact factor: 6.200

6.  Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials.

Authors:  Jeffrey L Saver; Gregory W Albers; Billy Dunn; Karen C Johnston; Marc Fisher
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

7.  VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.

Authors:  Yunjuan Sun; Kunlin Jin; Lin Xie; Jocelyn Childs; Xiao Ou Mao; Anna Logvinova; David A Greenberg
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

8.  Measurements of acute cerebral infarction: lesion size by computed tomography.

Authors:  T Brott; J R Marler; C P Olinger; H P Adams; T Tomsick; W G Barsan; J Biller; R Eberle; V Hertzberg; M Walker
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

9.  Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke.

Authors:  Andrew N Clarkson; Ben S Huang; Sarah E Macisaac; Istvan Mody; S Thomas Carmichael
Journal:  Nature       Date:  2010-11-03       Impact factor: 49.962

10.  Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin.

Authors:  Gregory Bix; Jian Fu; Eva M Gonzalez; Laura Macro; Amy Barker; Shelly Campbell; Mary M Zutter; Samuel A Santoro; Jiyeun K Kim; Magnus Höök; Charles C Reed; Renato V Iozzo
Journal:  J Cell Biol       Date:  2004-07-05       Impact factor: 10.539

View more
  14 in total

Review 1.  Roles of blood-brain barrier integrins and extracellular matrix in stroke.

Authors:  Danielle N Edwards; Gregory J Bix
Journal:  Am J Physiol Cell Physiol       Date:  2018-11-21       Impact factor: 4.249

2.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

3.  Inhibition of GABA transporters fails to afford significant protection following focal cerebral ischemia.

Authors:  Maria Ek Lie; Emma K Gowing; Rasmus P Clausen; Petrine Wellendorph; Andrew N Clarkson
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-17       Impact factor: 6.200

Review 4.  Basement Membrane Changes in Ischemic Stroke.

Authors:  Minkyung Kang; Yao Yao
Journal:  Stroke       Date:  2020-03-03       Impact factor: 7.914

5.  Perlecan Improves Blood Spinal Cord Barrier Repair Through the Integrin β1/ROCK/MLC Pathway After Spinal Cord Injury.

Authors:  Changnan Xie; Yihan Wang; Jinfeng Wang; Yizhou Xu; Haining Liu; Jiasong Guo; Lixin Zhu
Journal:  Mol Neurobiol       Date:  2022-10-10       Impact factor: 5.682

6.  The flavonoid, 2'-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia.

Authors:  Andrew N Clarkson; Lily Boothman-Burrell; Zita Dósa; Raghavendra Y Nagaraja; Liang Jin; Kim Parker; Petra S van Nieuwenhuijzen; Silke Neumann; Emma K Gowing; Navnath Gavande; Philip K Ahring; Mai M Holm; Jane R Hanrahan; Joseph A Nicolazzo; Kimmo Jensen; Mary Chebib
Journal:  J Cereb Blood Flow Metab       Date:  2018-01-29       Impact factor: 6.200

Review 7.  The potential role of perlecan domain V as novel therapy in vascular dementia.

Authors:  Aileen Marcelo; Gregory Bix
Journal:  Metab Brain Dis       Date:  2014-06-27       Impact factor: 3.584

8.  PEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia.

Authors:  Kim Parker; Antonio Berretta; Stefanie Saenger; Manaswini Sivaramakrishnan; Simon A Shirley; Friedrich Metzger; Andrew N Clarkson
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

9.  Lack of collagen XV is protective after ischemic stroke in mice.

Authors:  Hiramani Dhungana; Mikko T Huuskonen; Taina Pihlajaniemi; Ritva Heljasvaara; Denis Vivien; Katja M Kanninen; Tarja Malm; Jari Koistinaho; Sighild Lemarchant
Journal:  Cell Death Dis       Date:  2017-01-12       Impact factor: 8.469

Review 10.  The CNS/PNS Extracellular Matrix Provides Instructive Guidance Cues to Neural Cells and Neuroregulatory Proteins in Neural Development and Repair.

Authors:  James Melrose; Anthony J Hayes; Gregory Bix
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.